The Size of Active Implantable Medical Devices market in the Asia Pacific is anticipated to grow at 8.45% CAGR from 2019 to 2024 and it is estimated that the Asia-Pacific market is valued at USD 4.28 billion in 2019 and is expected to reach USD 6.43 billion by 2024 during the forecast period 2019-2024.
The Active Implantable Medical Device (AIMD) Directive 90/385/EEC defines an active implantable medical device as "any active medical device which is intended to be totally or partially introduced, surgically or medically, into the human body or by medical intervention into a natural orifice, and which is intended to remain after the procedure". As one of the highest risk categories of device, they are subject to severe regulatory controls both pre- and post-market. The regulatory controls set out in the AIMD Directive also apply to any accessories that are used to enable the device to operate as intended, for example leads, programmers, controllers, battery packs, software applications, implant kits, and refill kits.
The demand for active implantable medical devices is rising due to an increase in the prevalence of cardiovascular diseases and an increase in the incidence of neurological disorders. Cardiovascular disease is the leading cause of premature death around the world. Implantable cardioverter defibrillators and implantable cardiac pacemakers are the main medical devices used for the treatment of different cardiovascular conditions. The high prevalence of cardiovascular diseases depicts an increase in the demand for these devices.
According to the World Health Organization WHO, globally, around 17.5 million people died due to cardiovascular diseases in 2012, while the number is anticipated to reach 23.3 million by 2030. Factors such as advancement in technological, increase in the prevalence of cardiovascular diseases, rise in the healthcare expenditures by patients and increase in the research and development activities are the major factors driving the growth of the global active implantable medical devices market. However, the high cost of implantable medical devices and unfavorable reimbursement guidelines pose a crucial challenge thereby limiting the adoption of active implantable medical devices solutions.
Asia Pacific Active Implantable Medical Devices Market segmented and sub-segmented into the following categories.
On the basis of product, the neurostimulators market is anticipated to witness the highest growth rate during the forecast period. The demand for neurostimulators, especially deep brain stimulators is growing significantly across the globe. An increase in the prevalence of chronic pain, such as neuropathic pain, pain due to diabetes, arthritis pain and pain from an injury has increased the demand for neurostimulators significantly.
On the basis of region, the market in the Asia-Pacific region is expected to grow at the highest CAGR, due to the rise in geriatric population, growth in the occurrence of chronic diseases, rise in healthcare spending, healthcare reforms for infrastructural development, growth in the demand for advanced technologies to develop advanced products, and less strict regulations.
The countries such as China and India have a large geriatric population and the healthcare infrastructure in these countries is improving, thus illustrating immense healthcare market potential.
Some of the Promising companies leading the Asia Pacific Active Implantable Medical Devices Market Profiled in the Report are Medtronic plc, Abbott Laboratories, Boston Scientific Corporation, BIOTRONIK SE & Co. KG, LivaNova PLC., Cochlear Limited, MED-EL, Sonova Holding AG, William Demant Holding A/S, and Nurotron Biotechnology Co. Ltd
1.Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 Epidemology
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 Product
5.1.1 Introduction
5.1.2 Implantable Cardioverter Defibrillators
5.1.2.1 Transvenous Implantable Cardioverter Defibrillators
5.1.2.1.1 Biventricular Implantable Cardioverter Defibrillators (ICDs)/Cardiac Resynchronization Therapy Defibrillators (CRT-Ds)
5.1.2.1.2 Dual-Chamber Implantable Cardioverter Defibrillators
5.1.2.1.3 Single-Chamber Implantable Cardioverter Defibrillators
5.1.2.2 Subcutaneous Implantable Cardioverter Defibrillator
5.1.3 Implantable Cardiac Pacemakers
5.1.4 Ventricular Assist Devices
5.1.5 Implantable Heart Monitors/Insertable Loop Recorders
5.1.6 Neurostimulators
5.1.6.1 Spinal Cord Stimulators
5.1.6.2 Deep Brain Stimulators
5.1.6.3 Sacral Nerve Stimulators
5.1.6.4 Vagus Nerve Stimulators
5.1.6.5 Gastric Electrical Stimulators
5.1.7 Implantable Hearing Devices
5.1.7.1 Active Hearing Implants
5.1.7.2 Passive Hearing Implants
5.1.5 Y-o-Y Growth Analysis, By Product
5.1.6 Market Attractiveness Analysis, By Product
5.1.7 Market Share Analysis, By Product
6. Geographical Analysis
6.1 Introduction
6.1.1 Regional Trends
6.1.2 Impact Analysis
6.1.3 Y-o-Y Growth Analysis
6.1.3.1 By Geographical Area
6.1.3.2 By Product
6.1.4 Market Attractiveness Analysis
6.1.4.1 By Geographical Area
6.1.4.2 By Product
6.1.5 Market Share Analysis
6.1.5.1 By Geographical Area
6.1.5.2 By Product
6.2 China
6.3 India
6.4 Japan
6.5 South Korea
6.6 Australia
7.Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8.Market Leaders' Analysis
8.1 Medtronic plc
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Financial analysis
8.1.4 Recent Developments
8.1.5 SWOT analysis
8.1.6 Analyst View
8.2 Abbott Laboratories
8.3 Boston Scientific Corporation
8.4 BIOTRONIK SE & Co. KG
8.5 LivaNova PLC.
8.6 Cochlear Limited
8.7 MED-EL
8.8 Sonova Holding AG
8.9 William Demant Holding A/S
8.10 Nurotron Biotechnology Co. Ltd.
9.Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10.Market Outlook and Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
Related Reports
